Alteration of the steroidogenesis in boys with autism spectrum disorders

Katarína Janšáková1, Martin Hill2, Diana Čelárová1, Hana Celušáková1, Gabriela Repiská1, Marie Bičíková2, Ludmila Máčová2 and Daniela Ostatníková1

Abstract
The etiology of autism spectrum disorders (ASD) remains unknown, but associations between prenatal hormonal changes and ASD risk were found. The consequences of these changes on the steroidogenesis during a postnatal development are not yet well known. The aim of this study was to analyze the steroid metabolic pathway in prepubertal ASD and neurotypical boys. Plasma samples were collected from 62 prepubertal ASD boys and 24 age and sex-matched controls (CTRL). Eighty-two biomarkers of steroidogenesis were detected using gas-chromatography tandem-mass spectrometry. We observed changes across the whole alternative backdoor pathway of androgens synthesis toward lower level in ASD group. Our data indicate suppressed production of pregnenolone sulfate at augmented activities of CYP17A1 and SULT2A1 and reduced HSD3B2 activity in ASD group which is partly consistent with the results reported in older children, in whom the adrenal zona reticularis significantly influences the steroid levels. Furthermore, we detected the suppressed activity of CYP7B1 enzyme readily metabolizing the precursors of sex hormones on one hand but increased anti-glucocorticoid effect of 7α-hydroxy-DHEA via competition with cortisone for HSD11B1 on the other. The multivariate model found significant correlations between behavioral indices and circulating steroids. From dependent variables, the best correlation was found for the social interaction (28.5%). Observed changes give a space for their utilization as biomarkers while reveal the etiopathogenesis of ASD. The aforementioned data indicate a direction of the future research with a focus on the expression and functioning of genes associated with important steroidogenic enzymes in ASD patients from early childhood to adrenarche.

Introduction
Autism spectrum disorders (ASD) represent a group of neurodevelopmental disorders with multifactorial etiopathogenesis. Several theories have been proposed regarding the cause of autism but no one has yet been definitely proven or disproved1–3. One of them is the extreme male brain theory describing ASD cognitive traits in toward to a male behavioral pattern in a sense of dominance of systemizing as a male feature at the expense of empathizing as a female feature1. This theory together with the fetal androgen theory of autism4 tries to find the cause of ASD in prenatal exposure to male steroid hormones dominantly testosterone (TST). Since TST plays an important role during early developmental stages of brain5, thus, these theories assume it might contribute to the development of autistic traits1. Moreover, this theory is supported by the fact that ASD is diagnosed in male individuals four times more likely than in females6. Studies performed on amniotic fluid found altered hormonal profile in a sense of higher level of androgens in children who turned to have ASD7,8. Active androgens are synthesized via two alternative pathways. The first of them is known as the classic “frontdoor” pathway with pregnenolone serving as androgen precursor, which underwent a conversion to DHEA and subsequently to androstenediol. These metabolic steps are catalyzed by CYP17A1 (in the
C17,20-lyase step) and (mostly adrenal) AKR1C3 enzyme, respectively. DHEA and androstenediol are readily sulfated by SULT2A1 in adrenal cortex and their sulfates serve as the stock pool for the production of active androgens of the adrenal origin as the production of androgens in early childhood of boys is limited to extra-gonadal tissues, such as adrenal, skin, etc. These sulfated primary androgens, may be subsequently deconjugated, and metabolized by HSD3B1 and HSD3B2 isoforms to androstenedione and TST and then to 5α/β-reduced 17-oxo- and 17β-androgens, respectively. In addition, the androstenedione may be readily converted to testosterone by adrenal AKR1C3. From the aforementioned substances, TST, 5α-dihydrotestosterone, and 11-oxo-testosterone are known as the most potent bioactive androgens. Besides the “frontdoor” pathway the dihydrotestosterone may be also formed by so called “backdoor” pathway. This pathway is based on a direct conversion of 5α/β-reduced pregnane steroids (C21) to their 5α/β-reduced androgen (C19) metabolites which is catalyzed by the same enzyme converting pregnenolone to DHEA (CYP17A1 in the C17,20-lyase step). These 5α/β-reduced androgen (C19) metabolites include also the most active androgen 5α-dihydrotestosterone. The “backdoor” pathway is crucial for androgen synthesis in marsupials but may also be active in various human steroid-related disorders. The extragonadal androgen synthesis via the “frontdoor” pathway primarily proceeds in adrenal zona reticularis (ZR), however, like the testicular activity, the ZR functioning is minor in early childhood.

Contrary, studies assessing postnatal androgen levels in ASD are indecisive. While some of them report high amount of androgens in ASD (mainly TST) other studies claim no changes, effect or relation of postnatal levels of various sex steroids on ASD\textsuperscript{11,12}. Higher level of androgens were observed in saliva of prepubertal ASD boys and girls\textsuperscript{13} as well as in urine of pubertal ASD boys compared to controls\textsuperscript{14}. Adult ASD males showed no differences in serum TST while its concentration in ASD women was higher compared to matched controls\textsuperscript{14}. In addition, no association between autistic traits assessed using the Autism-spectrum Quotient questionnaire (AQ) and salivary TST concentration in adult males were observed\textsuperscript{15}.

While research is primarily focused on sex hormones, the role of other steroids like glucocorticoids or mineralocorticoids in the pathogenesis of ASD does not often come under scrutiny. The impact of these hormones in the complexity and continuity of steroidal pathway\textsuperscript{16,17}, especially in relation to ASD is not fully described. The aim of this study was to analyze steroidal metabolic pathway in plasma of male children diagnosed with ASD and healthy neurotypical controls.

**Materials and methods**

This study was approved by the Ethical committee of the Faculty of Medicine, Comenius University, and the University Hospital in Bratislava, Slovakia and it is consistent with the 1964 Helsinki declaration and its later amendments.

Parents were aware of design of the study and the informed consent form was signed by both (if available) parents or caregivers of corresponding child.

**Diagnostics of autism**

Children suspected for the presence of autism spectrum disorder (ASD) by a pediatrician were recruited and diagnosed in Academic research center for autism, Faculty of Medicine, Comenius University in Bratislava. Children were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders 5\textsuperscript{th} edition (DSM-5)\textsuperscript{18}. The diagnostic process was comprised of the two diagnostic methods Autism Diagnostic Observation Schedule 2nd revision (ADOS-2)\textsuperscript{19} and Autism Diagnostic Interview-Revised (ADI-R)\textsuperscript{20} which are considered to be “gold standard” diagnostic tools for ASD assessment. Diagnostic procedures were performed by trained clinical psychologists and the decision was made after consensus in clinical judgment. Children who did not meet the described criteria despite their social and communication impairment were not included into the study.

ADOS-2 represents a standardized behavioral observation of ASD symptoms suitable for individuals of 12 months through adulthood on different developmental levels and language skills. It comprises of various structured and non-structured situations in which social, communicative and other behaviors relevant for ASD diagnosis are observed.

Diagnostics of ASD using ADI-R is an interview with the parent or a caregiver of a child. It follows the developmental history of the individual as well as presence of the most significant behaviors related to ASD diagnosis. ADI-R diagnostic tool provides categorical results for three following subdomains: quality of social interaction (A); communication and language (B); and repetitive, restricted and stereotyped interests and behavior (C).

**Participants and sample collection**

A total number of 86 pre-pubertal, preschool boys were included into the study. Sixty-two individuals were children diagnosed with autism (ASD, 4.4 ± 1.1 years) in module 1 and 24 age and sex-matched neurotypical controls (CTRL, 4.29 ± 0.95 years). Control children were chosen by pediatrician based on no history of ASD or other neurodevelopmental disorder.

Exclusion criteria for recruitment were as follows: presence of a systemic disease, acute illness, using antibiotics
or steroidal and non-steroidal drugs and present any other psychiatric disorder except ASD.

Blood samples were collected immediately after ADOS-2 diagnostic procedure into sterile EDTA tubes (Sarstedt, Nümbrecht, Germany) around 10 am. Blood taken from controls was collected at the same time. All samples were delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at −80 °C until the analysis.

ADOS-2, Module 1 description

Module 1 is selected on the basis of expressive language level and age and is intended for individuals who do not consistently use phrase speech and who are more than 31 months old. This module comprises of ten tasks, during which the administrator provides presses for social interaction and communication. Immediately after administering all tasks, the professional assigns the codes for each of the observed behaviors according to the diagnostic algorithm. After assigning codes to the behaviors, two separate domains can be calculated: social affect and restricted and repetitive behaviors in addition to overall total ADOS-2 score, which combines scores of these domains.

Steroid analysis

All steroids and their polar conjugates were analyzed using gas-chromatography tandem-mass spectrometry (GC-MS/MS). Whole procedure was performed according to Hill et al.21.

Statistical analysis

Age-adjusted linear model

Statgraphic centurion XV statistical software (Statpoint, Inc., Herndon, Virginia, USA) was used for this analysis. Linear model adjusted to constant age was used for the separation of variability in the dependent variable shared with age from the one explained by the health status i.e., ASD vs. CTRL. Data were transformed using a power transformation for achieving the homoscedasticity and symmetry of the data prior to their further processing. Residual analysis was used for the checking of the homogeneity and the distribution of the transformed data.

Multivariate regression with a reduction of a dimensionality, orthogonal projections to latent structure (OPLS/O2PLS)

SIMCA-P s12.0. (Umetrics AB, Umeå, Sweden) was used for the processing of the obtained data. OPLS/O2PLS was used for the assessment of the relationship between the analyzed steroids and ASD or behavioral parameters.

As a single dependent variable, the logarithm of the likelihood ratio that the subject is an individual having ASD to the probability that individual is a neurotypical control was chosen. Age of the ASD and CTRL individuals together with the concentrations of steroids were considered as predictors. The variability of these predictors was divided into two groups of mutually independent components. First, variability predictors related to the probability of the presence of the ASD disorder as a predictive component. Second, orthogonal components explaining the variability shared within the highly intercorrelated predictors. The relevant predictors were chosen via variable important statistics.

Multiple regression

Like the multivariate regression the ordinary least squares multiple regression was completed using the SIMCA software. This analysis approach was used without the reduction of dimensionality.

In all analyses, p value below 0.05 was considered as significant. Data are presented as regression coefficients with their t-statistics (the ratio of regression coefficient to its standard error).

Results

Circulating unconjugated and conjugated steroids were detected in plasma of children diagnosed with autism categorized in module 1, ASD, and age-matched neurotypical controls, CTRL.

The relationship between two independent variables i.e., group represented by CTRL or ASD and age and 83 individual potential predictors representing the hormones of steroid metabolic pathways were detected. Age-adjusted ANCOVA model revealed a significant difference in 20 steroids.

Significantly lower level of pregnenolone sulfate was observed in ASD compared to CTRL (F = 4.4, p = 0.040). Significantly lower level of progesterone was observed in ASD compared to CTRL (F = 7.6, p = 0.007). Metabolites of progesterone, 16α-hydroxyprogesterone (F = 7.7, p = 0.007), 20α-dihydroprogesterone (F = 4.2, p = 0.024) and cortisone (F = 6, p = 0.019) were lower in ASD compared to CTRL. Similarly, conjugated epipregnanolone, conjugated 5α-pregnan-3α,20α-diol (F = 10.3, p = 0.002), 5β-pregnan-3β,20α-diol (F = 9.3, p = 0.003), conjugated 5α-pregnan-3β,17α,20α-triol (F = 32.4, p < 0.001) and conjugated 5β-pregnan-3α,17,20α-triol (F = 7.4, p = 0.009) were also significantly lower in ASD compared to CTRL. All C19 steroids showing significant differences between ASD and CTRL were lower in ASD. This concern 7α-hydroxy-DHEA (F = 4.5, p = 0.037), 7-oxo-DHEA (F = 17.2, p < 0.001), conjugated 5-androstene-3β,16α, 17β-triol (F = 16.1, p < 0.001), androsterone sulfate (F = 7.5, p = 0.008), epandrosterone sulfate (F = 6.7, p = 0.012), etiocholanolone (3α,5β-THA) sulfate (F = 6.8, p = 0.011), epietiocholanolone sulfate (F = 12.7, p < 0.001), conjugated 5α-androstane-3β,17β-diol (F = 9.6, p = 0.004),
5β-androstan-3β,17β-diol ($F = 9.6, p = 0.004$), and 11β-hydroxytetrahydrodeéanol (11β-hydroxytetrahydrodeéanol ($F = 9.7, p = 0.003$). All concentrations are presented as a mean together with lower and upper 95% confidence interval in Table 1 for every marker individually. There were many markers showing trends and marginally non-significant differences between CTRL and ASD. Thus, results from these markers with $p$ value for the factor Group up to $p = 0.2$ are presented in the Table 1 as well while the results with $p$ value above $p = 0.2$ are not shown. It is obvious that these measures create a line from pregnenolone via a first important point of steroidogenesis, progesterone and its metabolites 20α-dihydroprogesterone and its conjugate and 16α-hydroxyprogesterone. This line is heading toward cortisol. Next changes might be seen in the metabolic pathway of progesterone via conjugated epipregnanolone, conjugated 5α-pregnan-3α,20α-diol, 5β-pregnan-3β,20α-diol, conjugated 5α-pregnan-3β,17α,20α-triol, conjugated 5β-pregnan-3α,17α,20α-triol. Reduced pregnanes may serve as precursors for formation of reduced androstanes, including androsterone or the most active androgen 5α-dihydrotestosterone via “backdoor” pathway. The changes in metabolic pathway of androgens were seen around the metabolism of DHEA, specifically its metabolites 7α-hydroxy/7-oxo-DHEA and conjugated 5-androsten-3β,16α,17β-triol. Androstan dienes crossing the metabolism of androgens like 11β-hydroxytetrahydrodeéanol, conjugated 5α-androstan-3β,17β-diol and conjugated 5β-androstan-3β,17β-diol as well as sulfates of reduced 17-αo androstanes, such as androsterone, epandrosterone, etiocholanolone, and epitiocholanolone showed changes as well.

The ratio of 17α-hydroxypregnenolone/pregnenolone sulfates which conversion is secured by CYP17A1 hydroxylase showed significant differences toward the higher level in ASD compared to CTRL ($F = 4.6, p = 0.035$). Same, higher cortisol/corticosterone ratio was higher in ASD compared to CTRL ($F = 4.8, p = 0.035$) (Table 2, Fig. 1).

The product to precursor ratios (PPRs) for steroids converted by CYP17A1 C17,20-lyase (Table 2 and Fig. 2) exhibited significantly higher ratios in ASD for DHEA/pregnenolone ($F = 5.2, p = 0.026$), their sulfates ($F = 7.4, p = 0.009$), androsterone/allopregnanolone ($F = 10.9, p = 0.002$) and epandrosterone/isopregnanolone ($F = 6.8, p = 0.12$). On the other hand, ratio of androsterone/allopregnanolone sulfates was significantly lower in ASD compared to CTRL ($F = 4.3, p = 0.041$).

Significantly different ratios of steroid conjugates to the corresponding unconjugated steroids (C/U), which may reflect the balance between sulfate transferase SULT2A1 on one side and sulfatase STS on the other one are shown in Table 2. The C/U was significantly higher in ASD for pregnenolone ($F = 12.3, p < 0.001$), 17α-hydroxypregnenolone ($F = 18.3, p < 0.001$), 17α dihydroxy-4-pregnene-3-one ($F = 22.9, p < 0.001$), allopregnanolone ($F = 6.7, p = 0.012$), isopregnanolone ($F = 8.6, p = 0.005$), 5α-pregnan-3α,17α,20α-triol ($F = 8.9, p = 0.006$), but significantly lower for 5α-pregnan-3β,17α,20α-triol ($F = 10.9, p = 0.002$), 5α-pregnan-3α,20α-diol ($F = 6.9, p = 0.011$), 5β-pregnan-3β,20α-diol ($F = 10, p = 0.002$), androsterone ($F = 22.1, p < 0.001$), and 5β-androstan-3α,17β-diol ($F = 10.8, p = 0.002$).

The PPRs ratios reflecting HSD3B2 activity in zona fasciculata showed significantly lower 17α-hydroxyprogesterone/17α-hydroxypregnenolone ($F = 4.8, p = 0.032$) and 17α-hydroxyprogesterone/17α-hydroxypregnenolone sulfate ratio ($F = 11.4, p = 0.001$) in ASD compare to CTRL.

Supplementary Fig. 1 illustrates the changes between CTRL and ASD in non-corticoid immunoprotective substances, while the relevant PPRs are shown in Table 2. The ratio of 7α-hydroxy-DHEA/DHEA, which may reflect the activity of CYP7B1 enzyme was significantly lower in ASD compare to CTRL ($F = 13.8, p < 0.001$), same the 7β-hydroxy-DHEA/DHEA ratio ($F = 6.8, p = 0.012$), which may reflect the same metabolic step as well as the CYP3A4 activity. Alternatively, the ratio of sulfated forms 5α-androsten-3β,16α,17β-triol/androstenediol, reflecting most probably the activities of CYP3A4 and CYP7B1, was higher in ASD compare to CTRL ($F = 14.1, p < 0.001$). The activity of HSD11B1 enzyme tended to lower values in ASD compare to CTRL as indicated by the following ratios: 7β-hydroxy-DHEA/7α-hydroxy-DHEA ($F = 13.8, p < 0.001$), 5α-androsten-3β,16α,17β-triol/5α-androstenediol ($F = 4.1, p = 0.047$), and cortisol/cortisone ($F = 4.4, p = 0.045$). From the ratios probably affected by AKR1C3 activity only the ratio androstenediol/DHEA ($F = 5.4, p = 0.24$) was significantly lower in ASD compare to CTRL ($F = 5.4, p = 0.024$).

Table 2 shows significant PPRs which may reflect the activity of AKR1C1 (Supplementary Fig. 2) such as 20α-dihydropregnenolone/pregnenolone ($F = 5.6, p = 0.021$), 5α-pregnan-3α,20α-diol/allopregnanolone sul fate ($F = 31.6, p < 0.001$), 5β-pregnan-3α,20α-diol/pregnanolone ($F = 4.5, p = 0.039$), and 5β-pregnan-3α,17α,20α-triol/17α-hydroxypregnenolone ($F = 6.4, p = 0.014$). These PPRs indicate higher AKR1C1 activity in ASD group.

The association between ASD as a predicted variable and relevant predictors represented by unconjugated and conjugated steroids was evaluated by OPLS and multiple regression with the explained 14.6% variability of ASD risk with the highest reached correlation 26.8% in social interaction (Table 3).

The predictors in the OPLS model explained 18.4% of the variability (14.5% after cross-validation) of the variability in the prediction of ASD. The relationship between specific behavioral subdomains of ADI-R and ADOS-2 representing predictive variables and predictors represented by
Table 1  Table showing concentrations of unconjugated and conjugated/sulfated circulating steroids in CTRL and ASD individuals with statistical significance up to $p = 0.2$.

| Steroid                                      | Abbreviation | Mean [µmol/l] (lower; upper 95% CI) | ANCOVA (factor ASD and covariate Age) F = F-value, p = p-value |
|-----------------------------------------------|--------------|-------------------------------------|---------------------------------------------------------------|
| C21Δ¹³ | Pregneneolone | Preg      | 0.799 (0.652, 0.977)               | ASD: $F = 2.6, p = 0.111$; Age: $F = 0.1, p = 0.748$ |
|       | Pregneneolone sulfate | PregC | 55 (46.2, 66.7) | 40 (35.4, 45.2) | ASD: $F = 44, p = 0.004$; Age: $F = 11.7, p = 0.001$ |
|       | 20α-Dihydropregneneolone | Preg20a | 0.585 (0.491, 0.7) | 0.475 (0.422, 0.536) | ASD: $F = 1.9, p = 0.171$; Age: $F = 1.5, p = 0.221$ |
|       | 20α-Dihydropregneneolone sulfate | Preg20aC | 168 (141, 202) | 136 (121, 153) | ASD: $F = 2, p = 0.164$; Age: $F = 0.2, p = 0.639$ |
| C19Δ⁵  | DHEA         | DHEA      | 1.49 (1.29, 1.73)               | ASD: $F = 3, p = 0.0088$; Age: $F = 2.5, p = 0.117$ |
|       | DHEA sulfate | DHEAC     | 159 (117, 217) | 105 (85.7, 130) | ASD: $F = 2.5, p = 0.12$; Age: $F = 10.6, p = 0.002$ |
|       | 7α-Hydroxy-DHEA | DHEA7α | 0.322 (0.241, 0.423) | 0.188 (0.151, 0.231) | ASD: $F = 45, p = 0.037$; Age: $F = 4.6, p = 0.035$ |
|       | 7-oxo-DHEA    | DHEA7o    | 0.207 (0.171, 0.25) | 0.103 (0.0906, 0.118) | ASD: $F = 17.2, p < 0.001$; Age: $F = 4.5, p = 0.038$ |
|       | Androstenediol | Adiol  | 0.298 (0.247, 0.36) | 0.219 (0.194, 0.248) | ASD: $F = 38, p = 0.056$; Age: $F = 1.6, p = 0.212$ |
|       | Androstenediol sulfate | AdiolC | 262 (18.4, 37.7) | 15.4 (12.3, 19.3) | ASD: $F = 3.2, p = 0.079$; Age: $F = 1.6, p = 0.213$ |
|       | Conjugated 5-androstene-3β,16α,17β-triol | AT16αC | 114 (93.7, 13.8) | 5.69 (4.93, 6.54) | ASD: $F = 16.1, p < 0.001$; Age: $F = 15.5, p < 0.001$ |
| C21Δ⁴  | Progesterone  | Prog      | 0.131 (0.103, 0.166) | 0.0725 (0.0607, 0.0864) | ASD: $F = 76, p = 0.007$; Age: $F = 2.4, p = 0.125$ |
|       | 17-Hydroxyprogesterone | Prog17 | 0.606 (0.508, 0.723) | 0.484 (0.431, 0.544) | ASD: $F = 23, p = 0.138$; Age: $F = 15.5, p < 0.001$ |
|       | 16α-Hydroxyprogesterone | Prog16a | 0.543 (0.436, 0.678) | 0.323 (0.28, 0.374) | ASD: $F = 7.7, p = 0.007$; Age: $F = 0.3, p = 0.561$ |
|       | 20α-Dihydroprogesterone | Prog20a | 0.105 (0.0906, 0.123) | 0.0788 (0.0718, 0.0868) | ASD: $F = 53, p = 0.024$; Age: $F = 0.3, p = 0.575$ |
|       | Cortisone     | E         | 120 (100.5, 138) | 90.9 (83.6, 99.2) | ASD: $F = 6, p = 0.019$; Age: $F = 0.2, p = 0.655$ |
| C21 5αβ-reduced | Conjugated 20α-dihydroprogesterone | Prog20αC | 0.848 (0.733, 0.971) | 0.677 (0.617, 0.743) | ASD: $F = 34, p = 0.07$; Age: $F = 6.5, p = 0.013$ |
|       | Isopregnaneolone (3β5α-THP) | P3b5a | 0.126 (0.0969, 0.164) | 0.0931 (0.0779, 0.111) | ASD: $F = 1.8, p = 0.182$; Age: $F = 4.4, p = 0.039$ |
|       | Isopregnaneolone (3β5α-THP) sulfate | P3b5aC | 5.15 (4.57, 5.79) | 4.3 (3.94, 4.68) | ASD: $F = 3, p = 0.0087$; Age: $F = 0.7, p = 0.402$ |
|       | Conjugated epipregnaneolone (3β5β-THP) | P3b5bC | 1.12 (0.974, 1.28) | 0.873 (0.785, 0.967) | ASD: $F = 41, p = 0.048$; Age: $F = 1.7, p = 0.197$ |
|       | Conjugated 5α,20α-tetrahydroprogesterone | P5a20αC | 0.333 (0.243, 0.462) | 0.225 (0.185, 0.276) | ASD: $F = 22, p = 0.144$; Age: $F = 1.2, p = 0.277$ |
|       | Conjugated 5α-pregnane-3α,20α-diol | P3a5a20αC | 9.39 (8.05, 10.9) | 6.19 (5.58, 6.85) | ASD: $F = 10.3, p = 0.002$; Age: $F = 2.5, p = 0.119$ |
|       | Conjugated 5α-pregnane-3β,20α-diol | P3b5a20αC | 156 (131, 186) | 120 (108, 134) | ASD: $F = 33, p = 0.071$; Age: $F = 0.6, p = 0.45$ |
|       | Conjugated 5β-pregnane-3α,20α-diol | P3a5b20αC | 2.13 (1.83, 2.47) | 1.79 (1.61, 1.99) | ASD: $F = 18, p = 0.182$; Age: $F = 1.8, p = 0.182$ |
|       | 5β-Pregnan-3β,20α-diol | P3b5b20αa | 0.269 (0.199, 0.366) | 0.124 (0.103, 0.15) | ASD: $F = 93, p = 0.003$; Age: $F = 4.6, p = 0.036$ |
|       | 17-Hydroxyallopregnanolone sulfate | P3a5α17C | 1.77 (1.47, 2.11) | 2.17 (1.95, 2.41) | ASD: $F = 2, p = 0.167$; Age: $F = 0, p = 0959$ |
Table 1 continued

| Steroid                        | Abbreviation | Mean [µmol/l] (lower; upper 95% CI) ANCOVA (factor ASD and covariate Age) F = F-value, p = p-value |
|--------------------------------|--------------|---------------------------------------------------------------------------------------------------|
| 17-Hydroxyprogrenolone         | P3a5b17      | 0.0169 (0.0141, 0.0204) 0.0209 (0.0185, 0.0237) ASD: F = 1.8, p = 0.185; Age: F = 81.6, p < 0.001 |
| 5α-Pregnane-3α,17,20α-triol    | P3a5a17a20a  | 0.55 (0.414, 0.711) 0.375 (0.293, 0.471) ASD: F = 2.2, p = 0.147; Age: F = 1.5, p = 0.223 |
| Conjugated 5α-pregnane-3β,17,20α-triol | P3b5a17a20aC | 4.81 (3.82, 6.02) 1.52 (1.28, 1.79) ASD: F = 32.4, p < 0.001, Age: F = 10.6, p = 0.002 |
| 5β-Pregnane-3α,17,20α-triol    | P3d5b17a20a  | 0.221 (0.182, 0.266) 0.275 (0.243, 0.31) ASD: F = 1.9, p = 0.171; Age: F = 7.4, p = 0.009 |
| Conjugated 5β-pregnane-3α,17,20α-triol | P3a5b17a20aC | 263 (21.7, 31.9) 17 (15, 19.2) ASD: F = 7.4, p = 0.009, Age: F = 25.2, p < 0.001 |
| C19 5α/β-reduced Androsterone (3α5α-THA) sulfate | A3a5aC | 75.4 (58.4, 96.8) 41.8 (35.5, 49.1) ASD: F = 7.5, p = 0.008, Age: F = 27.9, p < 0.001 |
| Epandrosterone (3β5α-THA) sulfate | A3b5aC | 23.1 (18.1, 29.6) 13.3 (11.2, 15.8) ASD: F = 6.7, p = 0.012, Age: F = 8.5, p = 0.005 |
| Etocholanolone (3β5β-THA) sulfate | A3a5bC | 2.88 (2.51, 3.3) 2.13 (1.96, 2.32) ASD: F = 6.8, p = 0.011, Age: F = 37.8, p < 0.001 |
| Epietiocholanolone (3β5β-THA) | A3b5b | 0.0325 (0.0249, 0.0419) 0.0229 (0.0191, 0.0272) ASD: F = 2.4, p = 0.125, Age: F = 2.4, p = 0.13 |
| Epietiocholanolone (3β5β-THA) sulfate | A3b5bC | 2.47 (2.02, 3.03) 1.37 (1.22, 1.55) ASD: F = 12.7, p < 0.001, Age: F = 25.2, p < 0.001 |
| 5α-Androstane-3α,17β-diol      | A3a5a17b     | 0.0761 (0.0577, 0.0862) 0.0646 (0.0597, 0.07) ASD: F = 27, p = 0.109, Age: F = 0.8, p = 0.389 |
| Conjugated 5α-androstane-3β,17β-diol | A3b5a17bC | 2.43 (1.96, 3.01) 1.62 (1.43, 1.84) ASD: F = 53, p = 0.026, Age: F = 9, p = 0.004 |
| Conjugated 5β-androstane-3α,17β-diol | A3a5b17bC | 0.248 (0.172, 0.356) 0.158 (0.129, 0.195) ASD: F = 23, p = 0.133, Age: F = 0.6, p = 0.434 |
| 5β-Androstane-3β,17β-diol      | A3b5b17b    | 0.0667 (0.0519, 0.0844) 0.0316 (0.0247, 0.0398) ASD: F = 96, p = 0.004, Age: F = 0.1, p = 0.784 |
| Conjugated 5β-androstane-3β,17β-diol | A3b5b17bC | 0.0944 (0.0641, 0.14) 0.0525 (0.0421, 0.0658) ASD: F = 34, p = 0.071, Age: F = 2.1, p = 0.151 |
| 11β-Hydroxyandrostenedione     | A211b        | 87.9 (713, 103) 109 (89, 119) ASD: F = 26, p = 0.111, Age: F = 4.9, p = 0.03 |
| 11β-Hydroxyetiocholanolone     | A3a5b11b    | 6.26 (5.58, 7.01) 4.61 (4.26, 4.98) ASD: F = 97, p = 0.003, Age: F = 0.1, p = 0.738 |
| 11β-Etiocholanolone sulfate   | A3a5b11bC   | 3.58 (2.73, 4.61) 2.27 (1.88, 2.72) ASD: F = 3.8, p = 0.055, Age: F = 4.5, p = 0.036 |

All data are presented as mean together with lower and upper 95% confidence interval; age-adjusted linear model was used for evaluation of differences between CTRL and ASD. Bold values denote significant differences between the analysed groups.

ASD autism spectrum disorder, CI confidence interval, CTRL control.
Table 2  Age-adjusted differences between controls and ASD patients for product to precursor ratios reflecting CYP17A1 activity in the 17-hydroxylase metabolic step, CYP17A1 activity in the C17,20-lyase metabolic step, ratios of conjugated to unconjugated steroid (C/U) reflecting a balance between sulfotransferase and sulfatase activities, steroid ratios reflecting the formation of immunomodulatory and immunoprotective steroids, product to precursor ratios reflecting HSD3B2 activity, steroid ratios of reflecting AKR1C1 activity.

| Steroid ratio—17-hydroxy/17-deoxy-steroid | Mean (lower; upper 95% CI) | ANCOVA |  |
|------------------------------------------|---------------------------|---------|---|
| 17-Hydroxyprogrenolone/pregnenolone, sulfates | 0.0859 (0.073, 0.1) 0.117 (0.11, 0.13) | ASD: F = 4.6, p = 0.035, Age: F = 1.1, p = 0.309 |  |
| 17-Hydroxyprogesterone/progesterone | 4.97 (3.96, 6.27) 6.99 (5.96, 8.23) | ASD: F = 2.9, p = 0.094; Age: F = 0.7, p = 0.421 |  |
| Cortisol/corticosterone | 37.3 (30.7, 46.3) 57.3 (48.4, 68.6) | ASD: F = 4.8, p = 0.035, Age: F = 0.6, p = 0.455 |  |
| Steroid ratio, C19/C21-17-deoxy-steroid |  |
| DHEA/pregnenolone | 1.95 (1.73, 2.2) 2.49 (2.28, 2.73) | ASD: F = 5.2, p = 0.026, Age: F = 0.1, p = 0.784 |  |
| DHEA sulfate/pregnenolone sulfate | 2.42 (2.15, 2.75) 3.28 (3.1, 3.6) | ASD: F = 7.4, p = 0.009; Age: F = 2.29, p < 0.001 |  |
| Androsterone/allopregnanolone | 2.79 (2.43, 3.17) 3.92 (3.63, 4.22) | ASD: F = 10.9, p = 0.002; Age: F = 0.4, p = 0.515 |  |
| Androsterone/allopregnanolone, sulfates | 36.3 (30.7, 42.8) 27.2 (24.5, 30.1) | ASD: F = 4.3, p = 0.041; Age: F = 56.1, p < 0.001 |  |
| Epiandrosterone/isopregnanolone | 182 (1.65, 2) 2.27 (2.11, 2.43) | ASD: F = 6.8, p = 0.012, Age: F = 0.15, p < 0.001 |  |
| Steroid conjugate/unconjugated steroid ratio |  |
| Pregnenolone, C/U | 427 (35.8, 50.9) 70.8 (63.9, 78.4) | ASD: F = 12.3, p < 0.001, Age: F = 0.1, p = 0.828 |  |
| 17-Hydroxyprogrenolone, C/U | 205 (1.85, 2.28) 3.13 (2.88, 3.4) | ASD: F = 18.3, p < 0.001, Age: F = 1.7, p = 0.197 |  |
| 17,20a-Dihydroxy-4-pregnen-3-one, C/U | 267 (21.4, 3.34) 6.22 (5.54, 6.98) | ASD: F = 22.9, p < 0.001, Age: F = 0.8, p = 0.369 |  |
| Allopregnanolone (3α5α-THP), C/U | 304 (24.8, 37.2) 47.8 (41.7, 54.8) | ASD: F = 6.7, p = 0.012, Age: F = 0.4, p = 0.515 |  |
| Isopregnanolone (3β5α-THP), C/U | 265 (21.8, 31.8) 41.6 (37.4, 46.5) | ASD: F = 8.6, p = 0.005, Age: F = 19, p = 0.179 |  |
| 5α-Pregn-3α,17,20α-triol, C/U | 767 (88.9, 85.3) 102 (83.8, 110) | ASD: F = 8.9, p = 0.006, Age: F = 12.4, p < 0.002 |  |
| 5α-Pregn-3β,17,20α-triol, C/U | 342 (39.1, 45) 203 (18.3, 25.8) | ASD: F = 10.9, p = 0.002, Age: F = 0.5, p = 0.467 |  |
| DHEA, C/U | 120 (99.2, 146) 89.9 (79.1, 102) | ASD: F = 3.1, p = 0.081; Age: F = 12.7, p < 0.001 |  |
| Androstenediol, C/U | 777 (58.1, 103) 107 (88.3, 129) | ASD: F = 1.7, p = 0.192; Age: F = 3.5, p = 0.065 |  |
| 5α-Pregn-3α,20α-diol, C/U | 347 (28.6, 41.7) 22.5 (19.9, 25.5) | ASD: F = 6.9, p = 0.011, Age: F = 7.6, p = 0.008 |  |
| 5β-Pregn-3β,20α-diol, C/U | 22 (166, 29.3) 47.4 (39.4, 57.1) | ASD: F = 10, p = 0.002; Age: F = 4.2, p = 0.045 |  |
| Androsterone (3α5α-THA), C/U | 669 (535, 828) 265 (226, 309) | ASD: F = 22.1, p < 0.001, Age: F = 17.5, p < 0.001 |  |
| 5α-Androstan-3α,17β-diol, C/U | 219 (15.9, 30) 14.6 (12.1, 17.6) | ASD: F = 2.4, p = 0.126; Age: F = 0.1, p = 0.771 |  |
| 5β-Androstan-3α,17β-diol, C/U | 922 (5.71, 14.8) 2.44 (1.78, 3.34) | ASD: F = 10.8, p = 0.002; Age: F = 0.8, p = 0.368 |  |
Table 2 continued

| Enzyme | Steroid ratio                                      |  |  |  |
|--------|----------------------------------------------------|----------------|----------------|----------------|
| CYP7B1 | 7α-Hydroxy-DHEA/DHEA                               | 0.22 (0.18, 0.26) | 0.12 (0.1, 0.14) | ASD: F = 13, p < 0.001; Age: F = 3.9, p = 0.052 |
| CYP3A4 | 5-Androstene-3β,16α,17β-triol/androstenediol, sulfates | 0.246 (0.21, 0.28) | 0.342 (0.377, 0.48) | ASD: F = 14.1, p < 0.001; Age: F = 0, p = 0.911 |
| HSD11B1 | 7-α-OxodHEA/7α-Hydroxy-DHEA                       | 0.0776 (0.07, 0.09) | 0.0587 (0.05, 0.06) | ASD: F = 6.8, p = 0.012; Age: F = 0.1, p = 0.741 |
| CYP3A4 | 5-Androstene-3β,16α,17β-triol/5-Androstene-3β,17β-triol | 0.22 (0.18, 0.26) | 0.0726 (0.064, 0.086) | ASD: F = 13, p < 0.001; Age: F = 12.2, p < 0.001 |
| CYP3A4 | Cortisol/cortisone                                 | 2.88 (2.56, 3.29) | 2.35 (2.2, 2.52) | ASD: F = 11.5, p = 0.002 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 0.673 (0.59, 0.76) | 0.857 (0.8, 0.92) | ASD: F = 4.3, p = 0.039; Age: F = 0.5, p = 0.047 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 3.55 (2.8, 3.84) | 3.92 (3.72, 4.14) | ASD: F = 2.2, p = 0.141; Age: F = 26, p = 0.111 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 4.43 (3.46, 5.62) | 6.39 (5.52, 7.38) | ASD: F = 3.4, p = 0.069; Age: F = 3.3, p = 0.074 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 3.78 (3.09, 3.95) | 5.35 (4.99, 5.74) | ASD: F = 21.0, p < 0.001; Age: F = 0, p = 0.044 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 2.3 (1.98, 2.66) | 1.72 (1.38, 2.15) | ASD: F = 2.4, p = 0.13; Age: F = 4.2, p = 0.044 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 0.635 (0.58, 0.69) | 0.798 (0.7, 0.8) | ASD: F = 4.5, p = 0.039; Age: F = 19, p = 0.0179 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 281 (22.7, 34.3) | 40.6 (30.9, 52.3) | ASD: F = 2.5, p = 0.126; Age: F = 2.1, p = 0.16 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 911 (7.88, 10.5) | 12 (9.77, 14.7) | ASD: F = 2.4, p = 0.124; Age: F = 0.3, p = 0.568 |
| HSD17B2 | 20α-Dihydroxy-20α-Oxo-steroid                 | 597 (5.3, 6.7) | 8.56 (7.27, 10) | ASD: F = 6.4, p = 0.014; Age: F = 22.4, p < 0.001 |

All data are presented as means with 95% lower, upper 95% confidence intervals, only the variables with statistical significance up to p = 0.2 are shown. Bold values denote significant differences between the analysed groups. ASD autism spectrum disorder, CI confidence interval, CTRL control.
unconjugated and conjugated steroids were also evaluated by OPLS model (Supplementary Table 1).

**Discussion**

To our knowledge, this is the first study describing the markers of steroidogenesis across the whole pathway in plasma of boys diagnosed with ASD and neurotypical CTRL children. Only few studies dealing with the whole cascade of steroidogenesis have been published to this date, as majority of reports focus mostly on the narrow selection of the hormones and the bigger picture might be missing\textsuperscript{12,22}. The human steroidogenesis is strongly age-dependent, particularly in children and pubescents. Even if the children at the age of 6 have still negligible activity of adrenal zona reticularis\textsuperscript{23} some data indicate that adrenarche is a gradual process\textsuperscript{24}. Despite that exclusively pre-pubertal, pre-school children were recruited, a strong effect of age on the steroidogenic activity was observed. Therefore, firstly, our statistical analyses were age-adjusted and secondly, the comparisons of our data with other studies examining older children are limited.

Gasser et al. detected unconjugated steroids in urine of pubertal boys with ASD. They observed significantly higher level of most of the measured androstanes like androsterone,
etiocholanolone, androstenediol, 11β-hydroxyandrosterone, 11β-hydroxyetiocholanolone, DHEA, 5-androstene-3β, 17β-diol in ASD compared to CTRL. This fact might be explained by precocious adrenarche leading to premature puberty described even in individuals having ASD. Gasser et al. analyzed steroid pathway in pubertal individuals, thus, sexual maturity have to be critically taken into account. On the other hand, our results showed that sulfated androstanes like androsterone, epiandrosterone, etiocholanolone were lower in ASD group. This might be explained by the fact, that individuals recruited into our study were pre-pubertal boys while participants recruited into the study published by Gasser et al. were pubertal boys. Thus, the relation to the onset of the puberty mentioned above might represent a key factor in the comparison of these two studies.

Fig. 2 Simplified scheme illustrating differences between CTRL and ASD groups for CYP17A1 C17,20-lyase step. ↑/↓ denotes higher/lower steroid or steroid ratio in ASD group compare to control group; ASD, autism spectrum disorder; CTRL, control; $\delta$, sulfates; NA, hormone not assessed; (↑/↓), non-significant difference ↑/↓ significant difference between CTRL and ASD in favor to ASD with $p$ value up to $p = 0.2$ according to the results presented in Tables 1 and 2.
Table 3  Relationships between degree of autism and predictors for the 1st predictive component as evaluated by O2PLS model (for details see Statistical analysis).

| Variable | Component loading | t-statistics \( R^2 \) | Asum | Bsum | Csum | SAsum | ADOSRawscore |
|----------|--------------------|------------------|------|------|------|-------|--------------|
| Preg     | 0.250              | 8.59             | 0.020** | 0.035 | 6.26** | 0.017 | 360** | 0.017 | 3.60** |
| PregC    | 0.269              | 13.36            | 0.082** | 0.031 | 4.66** | 0.015 | 3.26** | 0.015 | 3.26** |
| Preg17   | 0.195              | 6.92             | 0.064** | 0.024 | 1.99*  | 0.012 | 1.63  | 0.012 | 1.63  |
| Preg17C  | 0.197              | 4.92             | 0.067** | 0.027 | 2.27*  | 0.013 | 1.91* | 0.013 | 1.91* |
| Preg20a  | 0.245              | 8.46             | 0.080** | 0.029 | 4.88** | 0.014 | 3.38** | 0.014 | 3.38** |
| Preg20aC | 0.275              | 24.17            | 0.901** | 0.033 | 4.64** | 0.016 | 3.88** | 0.016 | 3.88** |
| DHEA     | 0.275              | 27.71            | 0.902** | 0.034 | 6.28** | 0.016 | 4.41** | 0.016 | 4.41** |
| DHEAC    | 0.260              | 13.59            | 0.852** | 0.028 | 5.24** | 0.014 | 3.20** | 0.014 | 3.20** |
| DHEA7a   | 0.245              | 11.65            | 0.804** | 0.036 | 8.30** | 0.018 | 3.40** | 0.018 | 3.40** |
| AdiolC   | 0.274              | 24.24            | 0.899** | 0.039 | 7.13** | 0.018 | 4.25** | 0.018 | 4.25** |
| AT16aC   | 0.257              | 15.17            | 0.845** | 0.037 | 6.63** | 0.018 | 3.34** | 0.018 | 3.34** |
| A2       | 0.233              | 7.42             | 0.765** | 0.029 | 3.30** | 0.014 | 2.73*  | 0.014 | 2.73*  |
| P3b5a    | 0.226              | 5.14             | 0.748** | 0.038 | 6.10** | 0.019 | 3.33** | 0.019 | 3.33** |
| P3b5bC   | 0.245              | 10.48            | 0.802** | 0.029 | 4.93** | 0.014 | 2.84*  | 0.014 | 2.84*  |
| P3b5a20aC| 0.273              | 42.67            | 0.895** | 0.038 | 5.44** | 0.019 | 4.17** | 0.019 | 4.17** |
| A5a      | 0.201              | 10.61            | 0.665** | 0.029 | 3.37** | 0.014 | 6.56** | 0.014 | 6.56** |
| A3b11bC  | 0.211              | 10.29            | 0.693** | 0.035 | 4.08** | 0.017 | 3.07** | 0.017 | 3.07** |

| Explained variability | 14.6% (12.7% after a cross-validation) | 28.5% (26.8% after a cross-validation) | 10.5% (8.2% after a cross-validation) | 6.0% (5.1% after a cross-validation) | 17% (15.1% after a cross-validation) | 10.9% (8.5% after a cross-validation) |

Preg pregnenolone, Preg17 17-hydroxy-pregnenolone, Preg20a 20α-dihydroprogrenolone, DHEA dehydroepiandrosterone, DHEA7a 7α-hydroxy-DHEA, Adiol androstenediol, AT16a 5-androstene-3β,16α,17β-triol, A2 androstenedione, P3b5a isopregnanolone, P3b5b epipregnanolone, P3b5a20a 5α-pregnane-3β, 20α-diol, A5a 5α-androstane-3,17-dione, A3b11b 11β-hydroxyandrosterone, C conjugate/sulfate; ADI-R subdomains: Asum social interaction, Bsum communication and language, Csum repetitive, restricted and stereotyped interests.

\( R^2 \) Component loadings expressed as a correlation coefficients with predictive component

\*p < 0.05, \**p < 0.01.
Majewska et al.\textsuperscript{13} performed analysis of steroid hormones in saliva of autistic and control male and female children from two age groups, 3–4 and 7–9 years. They observed non-significantly higher level of pregnenolone and its sulfate in ASD compared to CTRL in the group of 3–4 years old boys. Concerning these substances, we observed similar results. In addition, they found lower levels of allopregnanolone and allopregnanolone sulfate in ASD in comparison with CTRL. Our results showed no significant differences in these hormones. Oppositely to our study, they also observed higher level of androsterone but also higher level of androsterone sulfate, etiocholanolone sulfate in 3–4 years old boys and epiandrosterone sulphate pointing to the changes in the alternative backdoor pathway of androgens production as well as higher activity of SULT2A1 in androgens.

We observed changes across the pathway from pregnenolone sulfate (lower in ASD), via progesterone toward 17-hydroxyprogesterone up to inactive cortisol metabolite corticosterone. Pregnenolone and its sulfate as neurosteroids play role in neurodevelopment and neural plasticity\textsuperscript{26}. It is currently well known, that pregnenolone has anxiolytic effects\textsuperscript{27} and plays role in improvement of depression symptoms\textsuperscript{28}. Sripada et al. showed that oral administration of pregnenolone could be associated with increased activation of neuronal circuits controlling emotion regulation\textsuperscript{29}. Even oral pregnenolone was used for adult individuals with ASD in the treatment of irritability and social withdrawal symptoms. It has been suggested the role of pregnenolone in improving social functioning, attenuating sensory abnormalities, and cognitive deficits\textsuperscript{30,31}. Since pregnenolone was found as ASD predictor based on OPLS model, there is a suggestion for its role as a biomarker or a therapeutic target.

Our results showed further changes in the pathway headed from progesterone via 20α–dihydroprogesterone, 17α-hydroxyallopregnanolone sulfates toward androsterone sulfate. At the same time, the unconjugated androsterone positively modulate type A GABA receptors and is neuroprotective like androstanediol\textsuperscript{32}, the levels of which were not significantly different between analyzed groups. The line of these changes is involved in the alternative backdoor pathway of androgens formation\textsuperscript{33}. The starting point of this pathway represents 17-hydroxyprogesterone\textsuperscript{34,35}. Although it did not significantly differ between observed groups CTRL and ASD, predictive component analysis assessed by OPLS model revealed it as one of the ASD predictors. We did not find any study investigating progesterone/17-hydroxyprogesterone and autism-like behavior.

Except the lower conjugated epipregnanolone in ASD, levels of 5α/β-reduced 20-oxo pregnanes were not changed. On the other hand, lower concentrations of 20α-dihydrometabolites (Table 1) were observed. Moreover, we detected lower PPRs of the 20α-hydroxy-pregnanes to their 20-oxo-counterparts (Table 2) indicate suppressed AKR1C1 activity in ASD group. Whereas the 20α-hydroxy-metabolites of GABAergic 20-oxo-pregnanes exhibit lower activity on type A GABA receptors than the parent steroids, this finding may be of importance.

Going ahead, the next metabolite in the alternative backdoor pathway is androsterone. However, its cognate metabolites like androsterone sulfate, epiandrosterone sulfate, etiocholanolone sulfate, epietiocholanolone sulfate, conjugated 5α-androstan-3β,17β-diol, 5β-androstan-3β,17β-diol, 11β-hydroxyetiocholanolone were lower in ASD proposing potential accumulation of androsterone in ASD. It should be pointed out that the adrenal possesses active adrenal zona reticularis only in children entering adrenarche but not in younger age. Therefore, the steroidogenesis in ASD subjects before and after adrenarche may substantially differ. The above 5α/β-reduced C19 steroids affect the functioning of a number of ionotropic and nuclear receptors. While androsterone (similar to etiocholanolone and androstanediol) is a positive type A GABA modulator and is, therefore, a neuroprotective substance, the sulphates of androsterone and epiandrosterone are their antagonists. In addition, these steroid sulphates work similarly on glycine receptors. Furthermore, unconjugated 5α/β-reduced steroids generally negatively modulate T-Type VGCCs that participate in the transmission of pain and unconjugated etiocholanolone similarly act on capsaicin receptors. Finally, a number of unconjugated 5α/β-reduced pregnanes and androstanes bind to nuclear pregnane X-type receptors (PXR), which are involved in the elimination of xenobiotics as well as endogenous toxic substances, including some steroids\textsuperscript{36}.

Our data indicate that ASD children before adrenarche demonstrate upregulated CYP17A1 activity (due to absence of functional zona reticularis) but this augmentation is mainly limited to the C17-hydroxylase step. The reduced activity of C17,20-lyase step at reduced levels of pregnenolone and its much more abundant sulfate might be associated with higher substrate consumption in the C17-hydroxylase step. However, the extra-adrenal activity of the C17,20-lyase step should be also considered. Same, the association between AQ and Asperger syndrome and CYP17A1 was found. Moreover, the relation between CYP17A1 single nucleotide polymorphism and ASD was described\textsuperscript{37}. Our data also indicate elevated sulfotransferase activity in ASD group based on the PPRs except androgens. The SULT2A1 is active in both zona fasciculata and zona reticularis even if the former adrenal zone is less active\textsuperscript{38}. It seems that androsterone might play an important strategic point in relation to ASD as well. In contrast to adrenal zona reticularis, which does not function in early childhood, the zona fasciculata (lacking the CYB5 enzyme, which blocks the HSD3B2, boosts the SULT2A1 activity and elicits the C17,20-lyase activity of the CYP17A1.
enzyme) readily converts 17-hydroxypregnenolone to 17-
hydroxyprogesterone. Our data demonstrate suppressed
activity of the HSD3B2 in the ASD group. These results
highlight the effect of these steroids in the pathogenesis of
ASD. Recent studies analyzing steroidogenesis as a com-
plex of hormones point to a crucial role of hormone-
converting enzymes. Hypothetically detection of a
candidate enzyme instead of hormone itself or its appro-
priate gene in sense of expression or polymorphism could
be helpful in diagnostics.

Although androsterone represents a weak androgen, it
acts as a positive allosteric modulator of GABA recep-
tors. Concentration of androsterone showed to be sex-
dependent, thus it might potentially related to the fact
that ASD is more diagnosed in males. Despite that
androsterone has weaker androgen activity in comparison
with TST its role is irreplaceable during the developmental
stage. Alternative backdoor pathway is strongly involved in
the masculinization of fetus. Androsterone was found
to be the most abundant androgen of the alternative
backdoor pathway present in the placenta, fetal liver and
adrenal glands. Abnormalities and disorders of the pla-
centa and their relation to ASD have already been des-
cribed, thus, it might be potentially related to the disruption
of alternative backdoor pathway. Moreover, it has been
hypothesized that backdoor pathway might be responsible
for extensive masculinization in women having congenital
adrenal hyperplasia. Disruption in the synthesis of these
hormones leading to their higher expression was observed
also in ovaries of women with polycystic ovary syndrome.
This condition was previously already associated with ASD
pattern and ASD development. Unfortunately, our
findings currently generalize only pre-pubertal male individu-
als. Although hormones of alternative backdoor pathway are
presented in females as well, their association with ASD
pathogenesis has to be clarified.

In our study, surprisingly, only few differences were
observed between ASD and CTRL in favor of group of
androgens. It has been described that 7α-hydroxy-DHEA
act as an anti-glucocorticoid. Our results showed a
relationship between DHEA, DHEAS, and androstene-
dione and both social skills deficits and restricted interest
in ASD.

Current studies, however, remain to be inconclusive
regarding the role of androgens in ASD etiology. Ruta et al.
did not find any relationship between DHEA sulfate, total
and free TST, and estradiol and ASD. However, regression
analysis in their study showed that diagnosis predicted
androstenedione levels, which were elevated in the serum in
ASD. On the other hand, El-Baz et al. found that hyper-
androgenemia with higher levels of free TST, DHEA, and
androstenedione increased with the autism severity. DHEAS possess neuroprotective effect e.g., by supporting
neurogenesis and neural survival by protecting against
apoptosis. Moreover, its positive impact on memory has
been described. However, memory impairment in a sense
of working memory or episodic memory has been observed
in ASD individuals. Except adrenal glands, DHEA/S is
produced in the brain as well. Nevertheless, the production
and metabolism of DHEA might vary between individual
brain regions. In the hippocampus, DHEA is further
metabolized to 7α-hydroxy-DHEA, which lower level was
observed in this study. Interestingly, differences in the hip-
 pocampal asymmetry and mass have been already reported
in ASD. Moreover, reduced hippocampal connectivity
during memory retrieval related to ASD was recently
observed. Since this study demonstrated significantly lower
levels of these hormones, their either measurement or tar-
geted therapy could be applied into the practice. The 7α/
β-hydroxy-, 16α-hydroxy- and 7-oxo-derivatives of C19 Δ5 steroids are effective immunomodulatory agents that
stimulate immune response on the one hand and suppress
autoimmune processes on the other. In addition, the 7-
oxogenated steroids act as so-called ergosteroids, activating
the enzymes glycero-3-phosphate dehydrogenase and a
malic enzyme. The final effect of ergosteroids may be
comparable to that of thyroid hormones.

Concerning the alterations of 7 and 16-oxygenated
metabolites of DHEA and androstenediol, our data
(Table 2) indicate the attenuated activity of the CYP7B1
enzyme but intensified 16α-hydroxylation of androstenediol
was probably catalyzed by CYP3A4 enzyme. While the CYP7B1 and CYP3A4 may inactivate the substrates
for the synthesis of active sex hormones this finding may be
associated with altered androgen levels of ASD
patients. Androstenediol represents a direct metabolite of DHEA having immunomodulating effect together with an
ability to stimulate immune response of the organism to
viral agents. A lower concentration of endogenous steroids, including DHEA was found to be related to
autoimmune diseases e.g., rheumatoid arthritis, multiple
sclerosis or inflammatory bowel disease. Higher
prevalence and susceptibility to autoimmune diseases,
inflammation, and abnormal immune reaction are com-
monly associated with ASD. Our results completed with
the results and observations from other studies show
the complexity of ASD pathogenesis.

Distribution of ASD between males and females shows
us that there must be a risk factor associated with being a
male presented in the etiopathogenesis of ASD. However,
looking only on TST might not fully explain these dif-
ferences. This is the first evidence of changes in alter-
native backdoor pathway in synthesis of androgens in
plasma of individuals with ASD. However, it seems that more than a hormonal change stands behind the pathology of ASD and altered hormonal profile might be a result of altered gene expression of hormones-associated or related genes\textsuperscript{64}. For this reason, steroid hormonal profile as well as genetic background with focusing on the alternative backdoor pathway of pre-pubertal girls, pubertal girls and boys, individuals during early and late adulthood and adults of both genders with ASD having various ASD severities should be further investigated. Moreover, ASD children included into this study were pre-pubertal children with very low communication skills and no phrase speech. Whether verbal individuals diagnosed with less severe ASD symptoms would share the same trend within the hormonal profile is questionable. However, the increased level of androgens positively correlated with the severity of ASD\textsuperscript{60} thus altered alternative backdoor pathway of androgens synthesis might be expected too. Confirmation of the observed changes in other subgroups and modules of ASD individuals could lead to diagnostic profiling and formation of diagnostic panel composed of groups of steroids, converting enzymes and genes\textsuperscript{66}. Standardized diagnostic approaches would emphasize diagnostic power of profiling by behavioral description and application of selected diagnostic scores with predictive variables.

The main limitation of this study is a missing evaluation of cholesterol as a precursor for steroid hormones synthesis. Unfortunately, some of the major hormonal steroids being the important intermediates and products like 5α-dihydrotestosterone, which would have emphasized our findings, were not detected. Unfortunately, we did not detected mineralocorticoids like aldosterone using the GC-MS/MS due to the chemical nature of these molecules\textsuperscript{21}. Another limitation might be that control children in the control group did not undergo the diagnostic procedure ADOS-2 and ADI-R.

In conclusion, in spite of scarce differences in circulating steroids between ASD and CTRL group, our data obtained from boys in early childhood indicate augmented activities of CYP17A1 hydroxylase step and SULT2A1 at reduced HSD3B2 activity in ASD group. This finding is consistent with the results reported in older children, in whom the adrenal zona reticularis significantly influences the steroid levels. Furthermore, we detected the suppressed activity of CYP7B1 enzyme readily metabolizing the precursors of sex hormones on one hand but increased anti-gluocorticoid effect of 7α-hydroxy-DHEA via competition with cortisone for HSD11B1 on the other hand. Analyses of the steroidogenesis revealed changes in those hormones involved in the alternative backdoor pathway of androgens production. This finding might be considered as a crucial since only changes in dominant metabolites were believed to contribute to ASD development. Looking for the origin of these differences and changes might reveal the potential biomarkers and shed a light into the ethiopathogenesis of autism.

Acknowledgements
The study was supported by the Slovak Research and Development Agency grant number [APVV 15-0045] and [APVV 15-0085] and MZ CR 00023761 “Long-term conceptual development of the organization (Institute of Endocrinology) based on already reached results”.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41398-020-01017-8).

Received: 30 October 2019 Revised: 4 September 2020 Accepted: 4 September 2020
Published online: 06 October 2020

References
1. Baron-Cohen, S. The extreme male brain theory of autism. Trends Cogn. Sci. 6, 248–254 (2002).
2. Kimhi, Y. Theory of mind abilities and deficits in autism spectrum disorders. Top. Lang. Disord. 34, 329–343 (2014).
3. Premack, D. & Woodruff, G. Does the chimpanzee have a theory of mind? Behav. Brain Sci. 1, 515–526 (1978).
4. Baron-Cohen, S. et al. Why are autism spectrum conditions more prevalent in males? PLoS Biol. 9, e1001081 (2011).
5. Filova, B., Ostamtkova, D., Colec, P. & Hodosy, J. The effect of testosterone on the formation of brain structures. Cells Tissues Organs 197, 169–177 (2013).
6. Næg, H. E., Nordgrön, A., Anfельt, B. M. & Næerland, T. Reversed gender ratio of autism spectrum disorder in Smith-Magenis syndrome. Mol. Autism 9, 1 (2018).
7. Baron-Cohen, S. et al. Elevated fetal steroidogenic activity in autism. Mol. Psychiatry 20, 369–376 (2015).
8. Ayueung, B., Taylor, K., Hackett, G. & Baron-Cohen, S. Foetal testosterone and autistic traits in 18 to 24-month-old children. Mol. Autism 1, 11 (2010).
9. Miller, W. L. & Auchus, R. J. The “backdoor pathway” of androgen synthesis in human male sexual development. PLoS Biol. 17, e300198 (2019).
10. Miller, W. L. & Auchus, R. J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32, 81–151 (2011).
11. Ayueung, B. et al. Prenatal versus postnatal sex steroid hormone effects on autistic traits in children at 18 to 24 months of age. Mol. Autism 3, 17 (2012).
12. Geisser B. A., Kurz J., Dick B. & Mohaupt M. G. Steroid metabolites support evidence of autism as a spectrum. Behav Sci (Basel) 9, 52 (2019).
13. Majewska, M. D. et al. Marked elevation of adrenal steroids, especially androgens, in saliva of prepupal autistic children. Eur. Child Adolesc. Psychiatry 23, 485–498 (2014).
14. Bjerent, S. et al. The extreme male brain revisited: gender coherence in adults with autism spectrum disorder. Br. J. Psychiatry. 201, 116–123 (2012).
15. Tan, D. W. et al. No relationship between autistic traits and salivary testosterone concentrations in men from the general population. PLoS ONE 13, e0198779–e0198779 (2018).
16. Patel, N., Crider, A., Pandya, C. D., Ahmed, A. O. & Pillai, A. Altered mRNA levels of glucocorticoid receptor, mineralocorticoid receptor, and co-pherones (PBRs and PTGSS) in the middle frontal gyrus of autism spectrum disorder subjects. Mol. Neurobiol. 53, 2090–2099 (2016).
17. Ogawa, S., Lee, Y. A., Yamaguchi, Y., Shibata, Y. & Goto, Y. Associations of acute and chronic stress hormones with cognitive functions in autism spectrum disorder. Neuroscience 343, 229–239 (2017).
18. Diagnostic and statistical manual of mental disorders: DSM-5\textsuperscript{TM}, 5th edn. pp xiv, 947–947 (American Psychiatric Publishing, Inc. Arlington, VA, US, 2013).
19. Lord, C. et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J. Autism Dev. Disord. 30, 205–223 (2000).
20. Lord, C., Rutter, M. & Le Couteur, A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. The Autism Dev. Disord. 24, 659–685 (1994).
21. Hill, M. et al. A method for determination of one hundred endogenous steroids in human serum by gas chromatography-tandem mass spectrometry. Physiol. Res. 68, 179–207 (2019).
22. Majewska M. D. et al. Marked elevation of adrenal steroids, especially androgens, in saliva of prepubertal autistic children. (1435–1615X (Electronic)).
23. Rege, J. & Rainey, W. E. The steroid metabolome of adrenarche. J. Endocrinol. 214, 131–143 (2012).
24. Palmiter, M. R. et al. The longitudinal study of adrenal maturation during gonadal suppression: evidence that adrenarche is a gradual process. J. Clin. Endocrinol. Metab. 86, 4536–4542 (2001).
25. Winter, S., Durand, A. & Brauner, R. Precocious and early central puberty in infancy and childhood. Pediatr. Endocrinol. Rev. 7, 117–129 (2004).
26. Vaille, M. Neurosteroids and potential therapeutics. Focus on pregnenolone. J. Steroid Biochem Mol. Biol. 160, 78–87 (2016).
27. Le Mellelo, J. M. & Baker, G. B. Neuroactive steroids and anxiety disorders. J. Psychiutry Neurosci.: Jan. 27, 161–165 (2002).
28. Brown, E. S. et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology 39, 2867–2873 (2014).
29. Sripatha, R. K. et al. Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuit. Biol. Psychiatry 73, 1045–1053 (2013).
30. Man, C. E. et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 34, 1885–1903 (2009).
31. Fung, L. K., Libove, R. A., Phillips, J., Haddad, F. & Hardan, A. Y. Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder. J. Autism Dev. Disord. 44, 2971–2977 (2014).
32. Reddy, D. S. & Etes, W. A. Clinical potential of neurosteroids for CNS disorders. Trends Pharmacol. Sci. 37, 543–561 (2016).
33. Aichus, R. J. The backdoor pathway to dihydrotestosteron. Trends Endocrinol. Metab. 15, 432–438 (2004).
34. O'Shaughnessy, P. J. et al. Alternative (backdoor) androgen production and masculinization in the human fetus. PLoS Biol. 17, e3000002 (2019).
35. Fukami, M., Homma, K., Hasegawa, T. & Ogata, T. Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development. Developmental Dyn. 242, 320–329 (2013).
36. Honcu, P. et al. Activation of adrenal steroidogenesis and an improvement of mood balance in postmenopausal females after spa treatment based on physical activity. Int. J. Mol. Sci. 20, 3687 (2019).
37. Chakrabarti, B. et al. Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and Asperger syndrome. Autism Res. 2, 157–177 (2009).
38. Nakamura, Y., Gang, H. X., Suzuki, T., Sasano, H. & Rainey, W. E. Adrenal changes associated with adrenarche. Rev. Endocrin. Metab. Disord. 10, 19–26 (2009).
39. Kaminski, R. M., Mannini, H., Kirm, W. J. & Rogowski, M. A. Anticonvulsant activity of dihydrotestosterone and etiocholanolone. Epilepsia 46, 819–827 (2005).
40. Fluck, C. E. et al. Why boys will be boys: two pathways of fetal testicular and adrenal androgen biosynthesis are needed for male sexual differentiation. Am. J. Hum. Genet. 89, 201–218 (2011).
41. Straughen, J. K. et al. The association between placental histopathology and autism spectrum disorder. Placenta 57, 183–188 (2017).
42. Hiort, O. The differential role of androgens in early human sex development. BMC Med. 11, 152 (2013).
43. Marn, N. et al. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 441, 116–123 (2017).
44. Katsiigiani, M., Karageorgiou, V., Lambrinoudaki, I. & Siristatidis, C. Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. Mol. Psychiatry 24, 1787–1797 (2019).
45. Kosidou, K. et al. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Mol. Psychiatry 21, 1441–1448 (2016).
46. Wetling, D. M. The role of sex-differential biology in risk for autism spectrum disorder. Biol. Sex differences 7, 58 (2016).
47. Ferri, S. L., Abel, T. & Brodkin, E. S. Sex differences in autism spectrum disorder: a review. Curr. Psychiatry Rep. 20, 9 (2018).
48. Muller, C., Pompon, D., Urban, P. & Morfin, R. Inter-conversion of 7alpha- and 7beta-hydroxy-dehydroepiandrosterone by the human 11beta-hydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol. 99, 215–222 (2006).
49. Ruta, L., Ingudomnukul, E., Taylor, K., Chakrabarti, B. & Baron-Cohen, S. Increased serum androstenedione in adults with autism spectrum conditions. Psychoneurosychopharmacology 36, 1154–1163 (2011).
50. Ehsanz, F., Hamza, R. T., Ayad, M. S. & Mahmoud, N. H. Hyperandrogenemia in male autistic children and adolescents: relation to disease severity. Int. J. Adolesc. Med. Health 26, 79–84 (2014).
51. Starka, L., Duska, M. & Hill, M. Dehydroepiandrosterone: a neuroactive steroid. J. Steroid Biochem. Mol. Biol. 145, 254–260 (2015).
52. Habib, A., Harris, L., Pollick, F. & Melville, C. A meta-analysis of working memory in individuals with autism spectrum disorder. PLoS ONE 14, e0216198 (2019).
53. Southwick, J. S. et al. Memory functioning in children and adolescents with autism. Neuropsychology 25, 702–710 (2011).
54. Richards, R. et al. Increased hippocampal shape asymmetry and volumetric ventricular asymmetry in autism spectrum disorder. Neuroumage Clin. 26, 102207 (2020).
55. Reinhardt, V. P. et al. Understanding hippocampal development in young children with autism spectrum disorder. J. Am. Acad. Child Adolesc. Psychiatry. 59, 1069–1079 (2019).
56. Cooper, R. A. et al. Reduced Hippocampal Functional Connectivity During Episodic Memory Retrieval in Autism. Genet. Cortex 27, 888–902 (2017).
57. Packdett, D. A. & Sheldon, J. F. Androstenediol (AED) prevents neuroendocrinemediated suppression of the immune response to an influenza viral infection. J. Neuroimmunol. 98, 121–129 (1999).
58. Auci, D. et al. Anti-inflammatory and immune regulatory properties of 5-androstene-3beta, 17beta-diol (HE2100), and synthetic analogue HE3204: implications for treatment of autoimmune diseases. Ann. N. Y. Acad. Sci. 1051, 730–742 (2005).
59. Gubbels, R., Bump, M. R. & Jorgensen, T. N. Androgen-Induced Immunosuppresion Front. Immunol. 9, 794 (2018).
60. Klaus, J., Reinschagen, M., Adler, G., Boehm, B. & von Tippitz, C. Bones and Crohn’s: estradiol deficiency in men with Crohn’s disease is not associated with reduced bone mineral density. BMC Gastroenterol. 8, 48 (2008).
61. de la Torre, B., Hedman, M. & Befrits, R. Blood and tissue dehydroepiandrosterone sulphate levels and their relationship to chronic inflammatory bowel disease. Clin. Exp. Rheumatol. 16, 579–582 (1998).
62. Doshi-Velez, F. et al. Prevalence of Inflammatory Bowel Disease Among Patients with Autism Spectrum Disorders. Inflamm. Bowel Dis. 21, 2281–2288 (2015).
63. Gladszcz, D., Kowyczinska, A. & Hojazys, K. K. Immune abnormalities in autism spectrum disorder-could they hold promise for causative treatment? Mol. Neurobiol. 55, 6387–6435 (2018).
64. Sarachana, T. & Hu, V. W. Genome-wide identification of transcriptional targets of RORα reveals direct regulation of multiple genes associated with autism spectrum disorder. Mol. Autism 4, 13 (2013).
65. Hu, V. W. et al. Gene expression profiling of lymphoblasts from autistic and unaffected sib pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS ONE 4, e5775 (2009).